BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 16340021)

  • 1. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients.
    Chan DT; Poon WS; Chan YL; Ng HK
    Hong Kong Med J; 2005 Dec; 11(6):452-6. PubMed ID: 16340021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Favourable result for temozolomide in recurrent high-grade glioma].
    Taal W; van der Rijt CD; Sillevis Smitt PA; Kros JM; van Heuvel I; Enting RH; van den Bent MJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1393-9. PubMed ID: 15997692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide in the treatment of recurrent malignant glioma.
    Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
    Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
    Yung WK; Prados MD; Yaya-Tur R; Rosenfeld SS; Brada M; Friedman HS; Albright R; Olson J; Chang SM; O'Neill AM; Friedman AH; Bruner J; Yue N; Dugan M; Zaknoen S; Levin VA
    J Clin Oncol; 1999 Sep; 17(9):2762-71. PubMed ID: 10561351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
    Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B
    Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Temozolomide in the treatment of recurrent malignant glioma].
    Kobayashi H; Sawamura Y; Ishii N; Murata J; Iwasaki Y
    No Shinkei Geka; 2006 Dec; 34(12):1241-7. PubMed ID: 17154070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
    Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
    Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide chemotherapy in patients with recurrent malignant gliomas.
    Yang SH; Kim MK; Lee TK; Lee KS; Jeun SS; Park CK; Kang JK; Kim MC; Hong YK
    J Korean Med Sci; 2006 Aug; 21(4):739-44. PubMed ID: 16891823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma.
    Kocher M; Kunze S; Eich HT; Semrau R; Müller RP
    Strahlenther Onkol; 2005 Mar; 181(3):157-63. PubMed ID: 15756519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
    Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
    Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
    Chinot OL; Honore S; Dufour H; Barrie M; Figarella-Branger D; Muracciole X; Braguer D; Martin PM; Grisoli F
    J Clin Oncol; 2001 May; 19(9):2449-55. PubMed ID: 11331324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
    Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S
    Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
    Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
    Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
    Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
    Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
    Neyns B; Chaskis C; Joosens E; Menten J; D'Hondt L; Branle F; Sadones J; Michotte A
    Cancer Invest; 2008; 26(3):269-77. PubMed ID: 18317968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.